TY - JOUR
T1 - Recommendations for cognitive screening and management in multiple sclerosis care
AU - Kalb, Rosalind
AU - Beier, Meghan
AU - Benedict, Ralph H.B.
AU - Charvet, Leigh
AU - Costello, Kathleen
AU - Feinstein, Anthony
AU - Gingold, Jeffrey
AU - Goverover, Yael
AU - Halper, June
AU - Harris, Colleen
AU - Kostich, Lori
AU - Krupp, Lauren
AU - Lathi, Ellen
AU - LaRocca, Nicholas
AU - Thrower, Ben
AU - DeLuca, John
N1 - Publisher Copyright:
© The Author(s), 2018.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Purpose: To promote understanding of cognitive impairment in multiple sclerosis (MS), recommend optimal screening, monitoring, and treatment strategies, and address barriers to optimal management. Methods: The National MS Society (“Society”) convened experts in cognitive dysfunction (clinicians, researchers, and lay people with MS) to review the published literature, reach consensus on optimal strategies for screening, monitoring, and treating cognitive changes, and propose strategies to address barriers to optimal care. Recommendations: Based on current evidence, the Society makes the following recommendations, endorsed by the Consortium of Multiple Sclerosis Centers and the International Multiple Sclerosis Cognition Society: Increased professional and patient awareness/education about the prevalence, impact, and appropriate management of cognitive symptoms. For adults and children (8+ years of age) with clinical or magnetic resonance imaging (MRI) evidence of neurologic damage consistent with MS: As a minimum, early baseline screening with the Symbol Digit Modalities Test (SDMT) or similarly validated test, when the patient is clinically stable; Annual re-assessment with the same instrument, or more often as needed to (1) detect acute disease activity; (2) assess for treatment effects (e.g. starting/changing a disease-modifying therapy) or for relapse recovery; (3) evaluate progression of cognitive impairment; and/or (4) screen for new-onset cognitive problems. For adults (18+ years): more comprehensive assessment for anyone who tests positive on initial cognitive screening or demonstrates significant cognitive decline, especially if there are concerns about comorbidities or the individual is applying for disability due to cognitive impairment. For children (<18 years): neuropsychological evaluation for any unexplained change in school functioning (academic or behavioral). Remedial interventions/accommodations for adults and children to improve functioning at home, work, or school.
AB - Purpose: To promote understanding of cognitive impairment in multiple sclerosis (MS), recommend optimal screening, monitoring, and treatment strategies, and address barriers to optimal management. Methods: The National MS Society (“Society”) convened experts in cognitive dysfunction (clinicians, researchers, and lay people with MS) to review the published literature, reach consensus on optimal strategies for screening, monitoring, and treating cognitive changes, and propose strategies to address barriers to optimal care. Recommendations: Based on current evidence, the Society makes the following recommendations, endorsed by the Consortium of Multiple Sclerosis Centers and the International Multiple Sclerosis Cognition Society: Increased professional and patient awareness/education about the prevalence, impact, and appropriate management of cognitive symptoms. For adults and children (8+ years of age) with clinical or magnetic resonance imaging (MRI) evidence of neurologic damage consistent with MS: As a minimum, early baseline screening with the Symbol Digit Modalities Test (SDMT) or similarly validated test, when the patient is clinically stable; Annual re-assessment with the same instrument, or more often as needed to (1) detect acute disease activity; (2) assess for treatment effects (e.g. starting/changing a disease-modifying therapy) or for relapse recovery; (3) evaluate progression of cognitive impairment; and/or (4) screen for new-onset cognitive problems. For adults (18+ years): more comprehensive assessment for anyone who tests positive on initial cognitive screening or demonstrates significant cognitive decline, especially if there are concerns about comorbidities or the individual is applying for disability due to cognitive impairment. For children (<18 years): neuropsychological evaluation for any unexplained change in school functioning (academic or behavioral). Remedial interventions/accommodations for adults and children to improve functioning at home, work, or school.
KW - Multiple sclerosis
KW - cognition
KW - cognitive dysfunction
KW - rehabilitation
KW - remediation
KW - screening
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85056788162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056788162&partnerID=8YFLogxK
U2 - 10.1177/1352458518803785
DO - 10.1177/1352458518803785
M3 - Article
AN - SCOPUS:85056788162
SN - 1352-4585
VL - 24
SP - 1665
EP - 1680
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 13
ER -